Navigation Links
Second Part of the Griffin Securities Analyst Interview with Unilife Corp. CEO is Now Available
Date:10/26/2012

NEW YORK, Oct. 26, 2012 /PRNewswire/ -- Griffin Securities announced today that the second part of its two-part interview series with Alan Shortall, CEO of Unilife Corporation ("Unilife") (NASDAQ: UNIS; ASX: UNS) is now available, during which Mr. Shortall discusses Unilife's device platforms and new commercial opportunities.  The interview was conducted by Dr. Keith Markey, the Scientific Director of Griffin's research division.

Both videos from the two-part series and the associated transcripts are now available on the Unilife website at www.unilife.com. The videos are also available on YouTube: video 1: http://youtu.be/X-LbVnzk1W0; and video 2: http://youtu.be/tDTeWn6UJLQ.   

For Griffin Securities' reports on Unilife Corporation, including full disclosure statements, please contact Dr. Keith Markey at 212-514-7914 or via email, kmarkey@griffinsecurities.com.

About Unilife Corporation
Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife collaborates with pharmaceutical and biotechnology companies seeking innovative, differentiated devices that can enable or enhance the delivery of injectable drugs and vaccines supplied in either a liquid stable or lyophilized form. The Unifill syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of this diversified portfolio. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, bolus injectors, infusion pumps and targeted delivery systems. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit www.unilife.com.     

About Griffin Securities, Inc. ("Griffin Securities")
Griffin Securities, a FINRA (formerly known as the NASD) member firm with its principal office in New York, New York, USA is an investment banking firm providing corporate finance, merger and acquisitions, brokerage, and investment opportunities for institutional, corporate, and private clients. The analyst(s) are employed by Griffin Securities. Our research professionals provide important input into our investment banking and other business selection processes. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

Griffin Securities may from time to time perform corporate finance or other services for some companies described herein and may occasionally possess material, nonpublic information regarding such companies. This information is not used in preparation of the opinions and estimates herein. While the information contained in this report and the opinions contained herein are based on sources believed to be reliable, Griffin Securities has not independently verified the facts, assumptions and estimates contained in this report. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this report.

The information contained herein is not a complete analysis of every material fact in respect to any company, industry or security. This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of clients of Griffin Securities. It does not take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. Certain transactions - including those involving futures, options, and other derivatives as well as non-investment-grade securities - give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. The information contained in this report is subject to change without notice and Griffin Securities assumes no responsibility to update the report. In addition, regulatory, compliance, or other reasons may prevent us from providing updates.

General: UNIS-G

KEITH A. MARKEY, PH.D., M.B.A.
Scientific Director
Griffin Securities
Phone: 212-514-7914
KMARKEY@GRIFFINSECURITIES.COM


'/>"/>
SOURCE Griffin Securities, Inc.; Unilife Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
2. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
4. Elbit Imaging Ltd. Announces Second Quarter Results for 2012
5. China Nepstar Chain Drugstore Reports Second Quarter 2012 Financial Results
6. Millennium Surgical Corp. Named to Inc. 5000 List of Fastest Growing Private Companies for The Second Year
7. China Kanghui Holdings Reports Second Quarter 2012 Financial Results
8. Over 123 Million Medical Device Units Recalled in Second Quarter of 2012, Reaching an Eight-Quarter High, According to the ExpertRECALL Index
9. Concord Medical Reports Second Quarter 2012 Financial Results
10. ShangPharma Announces Second Quarter 2012 Results
11. Access Pharmaceuticals To Host Second Quarter Investor Call on Thursday, August 23, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery ... Okaloosa County Emergency Medical Services (EMS) ... and one LT2 van. Quality Emergency Vehicles in ... for the sale.  This is the latest in Demers, ongoing ... Vice President at Demers. --> Benoit LaFortune , ...
(Date:2/12/2016)... 12. Februar 2016  Sequent Medical, Inc. gab ... Patienten für eine Studie zur Sicherheit und Wirksamkeit ... für die Behandlung von rupturierten intrakraniellen Aneurysmen begonnen ... der Neuroradiologie an der Universitätsklinik Bicètre in ... CLARYS-Studie hat den ersten Patienten aufgenommen. ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a locally owned insurance ... drive that will raise funds earmarked to purchase computers and software for Mrs. Harrison’s ... “My school is in a low-income area and has more than 60 2nd and ...
(Date:2/12/2016)... ... ... Erlanger Agency has announced a new partnership in its ongoing community involvement ... the fight against breast cancer, fundraising for a local woman named Carmen, who is ... is a loving single mother of two boys who also serves as caregiver for ...
(Date:2/12/2016)... MIAMI, FLA (PRWEB) , ... February 12, 2016 , ... ... free dental implants to their Miami dental office. Beginning in January, Miami Dental ... traditional titanium. Miami Dental Specialists are the first office to be chosen by the ...
(Date:2/12/2016)... NY (PRWEB) , ... February 12, 2016 , ... ... of “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer ... Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately ...
(Date:2/12/2016)... ... 2016 , ... Homeowners now have a next generation tool ... leading brand of building products, has improved upon its industry-best array of home ... of the ColorView® Exterior Style and Color Selector. Created expressly for the iPad®, ...
Breaking Medicine News(10 mins):